AstraZeneca has added to its oncology pipeline by licensing a small-molecule KRAS inhibitor from Chinese biotech Usynova for $24 million upfront. The compound – called UA022 – targets the ...

Accordingly, the researchers next plan to investigate the extent to which individual KRAS mutations influence response to EGFR inhibitors, such as cetuximab. “Future personalized patient ...

ormer North Sumatra governor Edy Rahmayadi went on the offensive in the second round of the gubernatorial election debate on Wednesday in the provincial capital, challenging rival candidate Medan ...

Since the discovery of RAS gene mutations in DNA from human tumours around 40 years ago, KRAS has emerged as the most frequently mutated oncogene in human cancer, particularly in pancreatic ...

Roche also axed a trial for divarasib, specifically a phase 2/3 trial that was comparing the KRAS G12C inhibitor to docetaxel in the second-line treatment of non-small cell lung cancer (NSCLC).